IOVA IOVANCE BIOTHERAPEUTICS, INC.
Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR IOVANCE BIOTHERAPEUTICS, INC. (IOVA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: Strategic restructuring with 19% workforce reduction completed Sept 2025 to cut costs and extend cash runway
- • Updated financial risk: Raised $350M ATM equity facility with Jefferies in Aug 2025 to support operations and product commercialization
Get deeper insights on IOVANCE BIOTHERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.